B&K CORP-B (02396) saw its shares plummet by 8.38% during intraday trading on Monday, following a disappointing debut on the Hong Kong Stock Exchange.
The stock opened at HK$33.8 per share, significantly below its offer price of HK$38.2, reflecting investor skepticism or lack of confidence in the company's valuation. This weak debut led to a sharp decline in the stock's price during early trading.
B&K CORP-B is a China-based biopharmaceutical company specializing in protein-based therapies, particularly PDGF drugs for wound healing. The company raised approximately HK$600 million in net proceeds from its IPO, but the early drop in share price suggests challenges in gaining market traction.